Long-Term Efficacy and Safety of Zolpidem Extended-Release 12.5 mg, Administered 3 to 7 Nights Per Week for 24 Weeks, in Patients With Chronic Primary Insomnia: A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study

Benzer Materyaller

• Zolpidem Extended-Release 12.5 mg Associated with Improvements in Work Performance in a 6-Month Randomized, Placebo-Controlled Trial
  Yazar:: Erman, Milton, ve diğerleri
  Baskı/Yayın Bilgisi: (2008)
• Low-Dose Sublingual Zolpidem Tartrate is Associated with Dose-Related Improvement in Sleep Onset and Duration in Insomnia Characterized by Middle-of-the-Night (MOTN) Awakenings
  Yazar:: Roth, Thomas, ve diğerleri
  Baskı/Yayın Bilgisi: (2008)
• Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia
  Yazar:: Krystal, Andrew D., ve diğerleri
  Baskı/Yayın Bilgisi: (2010)
• Efficacy and Safety of Doxepin 1 mg, 3 mg, and 6 mg in Adults with Primary Insomnia
  Yazar:: Roth, Thomas, ve diğerleri
  Baskı/Yayın Bilgisi: (2007)
• Insomnia: clinical experience with Zolpidem (Sanval)
  Yazar:: Ya. I. Levin
  Baskı/Yayın Bilgisi: (2010-09-01)